Buchumschlag

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Jakob B. Seidelin
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Getting to the Heart of the Matter in IBD
von: Ashwin N. Ananthakrishnan
Veröffentlicht: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
von: Ramin Ebrahimi, et al.
Veröffentlicht: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
von: Daniele Noviello, et al.
Veröffentlicht: (2025)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
von: Darcy Quinn Holt, et al.
Veröffentlicht: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
von: James L. Alexander, et al.
Veröffentlicht: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
von: Parul Tandon, et al.
Veröffentlicht: (2025)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
von: Maria Ling Lundström, et al.
Veröffentlicht: (2024)

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
von: Keith Bodger
Veröffentlicht: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
von: Shabari Shenoy, et al.
Veröffentlicht: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
von: Christian P. Selinger, et al.
Veröffentlicht: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
von: Guofu Mao, et al.
Veröffentlicht: (2026)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
von: Fahim Ebrahimi, et al.
Veröffentlicht: (2024)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
von: Katherine L. Stone, et al.
Veröffentlicht: (2024)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
von: Xueneng Yang, et al.
Veröffentlicht: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
von: Samantha Baillie, et al.
Veröffentlicht: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
von: Giovanni Cammarota, et al.
Veröffentlicht: (2024)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
von: Adam S. Faye, et al.
Veröffentlicht: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
von: Alice S. Day, et al.
Veröffentlicht: (2025)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
von: Xinli Chen, et al.
Veröffentlicht: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
von: Olga M. Nardone, et al.
Veröffentlicht: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
von: Simone Chin, et al.
Veröffentlicht: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
von: Natassia Tan, et al.
Veröffentlicht: (2025)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
von: Amanda Ricciuto, et al.
Veröffentlicht: (2024)

Research Communication: Sexual Dysfunction is a Common Early Challenge in Newly Diagnosed Inflammatory Bowel Disease
von: Mohamed Attauabi, et al.
Veröffentlicht: (2025)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
von: Guilherme Grossi Lopes Cançado
Veröffentlicht: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability?
von: Joshua Reid, et al.
Veröffentlicht: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
von: C. M. Fernández‐Rodríguez, et al.
Veröffentlicht: (2024)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
von: Niharika Samala, et al.
Veröffentlicht: (2024)

Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?
von: Tarun Chhibba
Veröffentlicht: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2024)

Editorial: The unquenchable thirst for drinks and diets as treatments for constipation
von: Yoav Mazor, et al.
Veröffentlicht: (2024)

Editorial: The future of managing drug induced liver injury
von: Amanda Nicoll
Veröffentlicht: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
von: Giammarco Mocci, et al.
Veröffentlicht: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data
von: John David Chetwood, et al.
Veröffentlicht: (2024)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
von: Daniel Tassone, et al.
Veröffentlicht: (2024)